Methods for treating HCV

• US 8,809,265 B2
• Filed: 10/19/2012
• Issued: 08/19/2014
• Est. Priority Date: 10/21/2011
• Status: Active Grant

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbvie Incorporated
• Inventors: Bernstein, Barry M., Menon, Rajeev M., Khatri, Amit, Mensing, Sven, Dutta, Sandeep, Cohen, Daniel E., Podsadecki, Thomas J., Brun, Scott C., Awni, Walid M., Dumas, Emily O., Klein, Cheri E.
• Primary Examiner(s): Audet, Maury
• Assistant Examiner(s): Miknis, Zachary J
• Application Number:
  US13/656,012
• Publication Number:
  US 20130102526A1
• Time in Patent Office: 669 Days
• Field of Search: None
• US Class Current: 514/4.3
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/4196 1,2,4-Triazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4725 containing further heterocyclic rings
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Claims

1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein said treatment lasts for 8 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977 and an HCV NS5A inhibitor, and wherein said patient is a treatment-naï

ve patient infected with HCV genotype 1.

2. The method of claim 1, wherein said HCV NS5A inhibitor is Compound 4

3. The method of claim 1, wherein said PSI-7977 is administered at a dose of 400 mg once daily.

4. The method of claim 1, wherein said PSI-7977 and said HCV NS5A inhibitor are co-formulated in a single composition and administered once daily.

5. A method of treatment for HCV, comprising administering at least two DAAs to a patient infected with HCV genotype 1, wherein said treatment lasts for 6 or 7 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977, an HCV NS5A inhibitor and another DAA.

6. The method of claim 5, wherein said another DAA is Compound 1

7. The method of claim 5, wherein said PSI-7977 is administered at a dose of 400 mg once daily.

8. The method of claim 5, wherein said another DAA is an HCV protease inhibitor.

9. The method of claim 5, wherein said another DAA is an HCV polymerase inhibitor.

10. The method of claim 5, wherein said patient is a treatment naï

ve patient.

11. The method of claim 5, wherein said patient is an interferon non-responder.